Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24

BACKGROUND: The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30–40% of patients are non-responders or relapsers to such combination. OBJECTIVE: To analyse t...

Descripción completa

Detalles Bibliográficos
Autores principales: Saadoun, David, Resche Rigon, M, Thibault, V, Longuet, M, Pol, S, Blanc, F, Pialoux, G, Karras, A, Bazin-Karra, D, Cazorla, C, Vittecoq, D, Musset, L, Decaux, O, Ziza, J M, Lambotte, O, Cacoub, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995244/
https://www.ncbi.nlm.nih.gov/pubmed/23606708
http://dx.doi.org/10.1136/annrheumdis-2012-202770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995244/
https://www.ncbi.nlm.nih.gov/pubmed/23606708
http://dx.doi.org/10.1136/annrheumdis-2012-202770

Ejemplares similares